<DOC>
	<DOC>NCT00926575</DOC>
	<brief_summary>Use of an oral topically-active glucocorticoid with limited side effects will control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.</brief_summary>
	<brief_title>Study of orBecÂ® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Receipt of allogeneic hematopoietic cell transplant Diagnosis of GI graft vs. host disease (GVHD) No GI infection Must be able to swallow tablets Must be able to read and understand informed consent Adequate birth control methods for the duration of the study Significant Skin GVHD Liver GVHD Persistent vomiting HIV positive Pregnancy/lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>BDP</keyword>
	<keyword>orBec</keyword>
	<keyword>GVHD</keyword>
	<keyword>beclomethasone dipropionate</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>hematopoietic cell transplant</keyword>
	<keyword>HCT</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>marrow transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>beclomethasone 17,21-dipropionate</keyword>
</DOC>